Why UniQure Stock Is Soaring
Why UniQure Stock Is Soaring
"We are very pleased with these new data demonstrating a statistically significant, dose-dependent slowing of the progression of Huntington's disease and lowering of NfL in the CSF at 24 months," stated UniQure N.V. (NASDAQ:QURE) shares are trading higher Tuesday after the company announced updated interim data from its ongoing U.S. and European Phase I/II clinical trials of AMT-130 for the treatment of Huntington's disease.
UniQure N.V. (納斯達克：QURE)股票週二交易較高，因公司公佈了AMt-130治療亨廷頓病美國和歐洲的I / II期臨床試驗的最新中期數據。
The Details:
細節：
UniQure said a statistically significant, dose-dependent, slowing in disease progression measured by cUHDRS was observed through 24 months in patients receiving the high dose of AMT-130. The company also said it observed a statistically significant reduction of NfL in cerebrospinal fluid (CSF) in patients treated with AMT-130.
UniQure表示，接受高劑量AMt-130治療的患者有統計學意義的劑量依賴性疾病進展減緩，通過cUHDRS衡量，療程達24個月，該公司還表示，在接受AMt-130治療的患者的腦脊液（CSF）中觀察到了NfL的顯着統計學減少。
"We are very pleased with these new data demonstrating a statistically significant, dose-dependent slowing of the progression of Huntington's disease and lowering of NfL in the CSF at 24 months," stated Walid Abi-Saab, M.D., chief medical officer of UniQure.
“我們對這些新數據感到非常滿意，這些數據表明了亨廷頓病的統計顯着、劑量依賴性減緩和在24個月內降低CSF中的NfL，”UniQure的首席醫學官Walid Abi-Saab萬.D.說。
"We believe this is the first clinical trial of any investigational medicine for Huntington's disease to show evidence of a potential long-term clinical benefit and reduction of a key marker of neurodegeneration."
“我們認爲這是任何亨廷頓病研究藥物的第一項臨床試驗，顯示出潛在長期臨床益處和神經退行性關鍵標誌物的降低。”
The company said it expects to hold a Type B, multi-disciplinary RMAT meeting with the U.S. Food and Drug Administration (FDA) to present the updated data and discuss potential expedited clinical development pathways and accelerated approval in the second half of 2024.
該公司表示，預計在2024年下半年與美國食品和藥物管理局（FDA）舉行b型多學科RMAt會議，以展示更新的數據並討論潛在的加速臨床發展路徑和加速批准。
UniQure shares are moving on heavy trading volume following the company's announcement. According to data from Benzinga Pro, more than 27.7 million shares have already been traded in Tuesday's session, compared to the stock's 100-day average of less than 573,000 shares.
UniQure的股票公告後成交量激增。根據Benzinga Pro的數據，週二交易會話中已經交易了超過2770萬股，而該股票的100日平均交易量不到57.3萬股。
Is QURE A Good Stock To Buy?
QURE是否是一隻好股票？
Wall Street analysts view UniQure on the whole as a Buy, given the history of coverage over the past three months. Uy Ear from Mizuho in UniQure is the most bearish, expecting a 14.29% fall in the stock in the coming year.
綜合來看，華爾街分析師認爲UniQure是買入的，這是基於過去三個月的覆蓋歷史。除了Mizuho的Uy Ear，預計該股票將下跌14.29%。
But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past 3 months, UniQure rose 11.69%, which indicates that opinion improved on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which rose 59.34% over the past year.
但是，從市場整體對股票的看法來看，你可以參考歷史價格走勢，了解投資者對股票的看法是否有強烈的喜愛或厭惡。在過去的3個月中，UniQure上漲了11.69%，這表明基於股價或營業收入等基本面的投資者對公司和公司的吸引力的觀點已得到改善。
A complete overview of how Wall Street views individual stocks is available here, while real time updates on the latest analyst actions will be delivered via Benzinga PRO. Try it for free.
可以在此處獲得有關華爾街如何看待個股的完整概述，而最新分析師行動的實時更新將通過Benzinga PRO提供。立即免費試用。
QURE Price Action: According to Benzinga Pro, UniQure shares are up 59% at $6 at the time of publication Tuesday.
QURE價格行情: 根據Benzinga Pro的數據，UniQure股票上漲59%，報6美元，時間爲週二的出版時間。
Read Also:
閱讀更多：
- What's Going On With Nikola Stock?
- nikola股票的情況怎麼樣了？
Image: PublicDomainPictures from Pixabay
圖片來自Pixabay的PublicDomainPictures。